The most useful questions to ask before tesamorelin are about fit, not dosing. Is your goal close to what the drug was actually studied for? Does anything in your history rule it out, like active cancer, pregnancy or a pituitary problem? And what gets checked once it starts, mainly blood sugar and IGF-1, a blood marker of growth-hormone activity?
Below are 13 questions, grouped the way a review tends to run. Each comes with the reason it's asked, usually a line from the brand's prescribing information, Egrifta WR on DailyMed (Revised: 3/2025). Tesamorelin is a lab-made copy of growth hormone-releasing hormone, the signal that tells the pituitary gland to release growth hormone; what tesamorelin does covers the rest.
Questions to ask before tesamorelin about your goal
1. Has tesamorelin been studied for what I want it for?
The label covers one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy, a shift in where the body stores fat during HIV treatment. It adds that tesamorelin is "not indicated for weight loss management as it has a weight neutral effect."
In a 2007 trial of 412 adults with HIV, visceral fat, the deep fat packed around the organs, fell 15.2% over 26 weeks on tesamorelin and rose 5.0% on placebo (Falutz et al., NEJM 2007). Outside HIV, the main evidence is one 12-month trial of 60 adults with abdominal obesity and low growth-hormone output, where visceral fat fell about 35 cm² more than on placebo (Makimura et al., JCEM 2012). A good answer is honest about that gap; what off-label use means explains how use beyond a label works.
2. How will we know if it's working?
Not by the scale. In the main trials average weight barely moved and waists shrank only 1 to 2 cm more than on placebo; the change showed up on CT scans. The label asks prescribers to weigh continuing when visceral fat hasn't come down, so a good answer names something measurable and a date to check it.
Is tesamorelin right for me? The history that shapes the answer
3. Have I ever had cancer?
Tesamorelin raises growth hormone, a known growth signal, so active cancer is a contraindication, a firm reason not to use it. For past cancer the label is specific: "Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA WR." The trials excluded anyone with a cancer history, and lifetime cancer studies in rodents were never done. Tesamorelin side effects sets out what is and isn't known.
4. Could I be pregnant, am I planning to be, or am I breastfeeding?
Pregnancy is a contraindication because changing visceral fat "offers no benefit in a pregnant woman and could result in fetal harm." In rats, two to four times the human exposure caused hydrocephaly, fluid on the brain, in offspring. The label also says mothers taking it shouldn't breastfeed.
5. Have I had pituitary surgery, a pituitary tumor, head radiation or a serious head injury?
Tesamorelin works through the pituitary, so if that gland, or the brain signal above it, has been damaged, the label rules it out. Relatedly, people on steroid replacement for adrenal insufficiency may need a higher replacement dose once tesamorelin starts.
6. Have I reacted badly to an injection before?
Allergic-type reactions such as itching, hives and rash happened in 4% of people on tesamorelin in the trials, and a known allergy to it rules it out. Injection-site reactions were more common: about 1 in 4 people on the drug over the first 26 weeks, against about 1 in 7 on placebo. The label's answer is rotating injection spots across the abdomen.
Medicines, sport and the blend
7. Do any of my medicines or hormones interact with it?
Growth hormone can change how fast the liver clears some drugs; the label names corticosteroids, sex steroids, anticonvulsants and cyclosporine, and asks for monitoring rather than avoidance. The list also covers other growth-hormone peptides, including ones bought elsewhere, so nothing doubles up.
8. Do I compete in a tested sport?
As of September 23, 2026, the day this article was written, the World Anti-Doping Agency's 2027 Prohibited List, published September 21 and in force from January 1, 2027, names tesamorelin under S2.2.4 among substances prohibited at all times. Ipamorelin is on it too. A prescription alone doesn't settle it; WADA's route for a documented medical need is a therapeutic use exemption.
9. Would a tesamorelin and ipamorelin blend make more sense?
Ipamorelin nudges the pituitary through a different door, the ghrelin receptor. But no published trial has tested the two together, and every number on this page comes from tesamorelin alone. A good answer explains why the second peptide is being added; tesamorelin and ipamorelin goes through the evidence.
Before starting tesamorelin: the labs, and what happens over time
10. What's my blood sugar now, and how often will it be rechecked?
In the trials, 5% of people on tesamorelin reached an HbA1c of 6.5% or higher by week 26, against 1% on placebo. HbA1c is a three-month average of blood sugar, and 6.5% is where the label marks diabetes. The label asks for glucose checks before starting and periodically after, and for people with diabetes to be watched for retinopathy, damage to the back of the eye.
The main trials excluded people on diabetes medicines, but a 12-week trial in 53 adults with type 2 diabetes found no significant change in blood-sugar control (Clemmons et al., PLoS One 2017).
11. How will my IGF-1 be tracked, and what number would change the plan?
IGF-1 is a growth factor the liver makes in response to growth hormone, and it can overshoot. After 26 weeks, 47% of trial participants were more than two standard deviations above normal for their age, and 36% more than three. The label says the effects of long-term high IGF-1 "are unknown" and suggests considering stopping when it stays above about three, especially if the fat response is weak. A good answer names a baseline test, a recheck and that threshold.
12. What happens if I stop?
In the trials, the fat came back. People switched to placebo after 26 weeks saw visceral fat rise 16% to 22% over the next six months, while those who stayed on it held their reduction. The authors concluded the effects "do not last beyond the duration of treatment" (Falutz et al., AIDS 2008).
How long to stay on it is still open. As of September 23, 2026, the day this article was written, the newest pooled look was a July 31, 2026 meta-analysis of four trials and 909 people with HIV, which cited "limited data on long-term safety, optimal dosing strategies, and durability of treatment effects" (Ditta et al., 2026).
The question about the vial itself
13. Is this Egrifta, or a compounded preparation, and who makes it?
They aren't interchangeable; the Egrifta WR label says even the brand's own two versions "are not substitutable." Promise's tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Its concentration, storage and beyond-use date come from the pharmacy label. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
The real contrast is an online vial. As of September 23, 2026, the day this article was written, FDA had posted a warning letter dated August 24, 2026 telling one online seller that its tesamorelin and tesamorelin-ipamorelin products, labeled for laboratory use, were unapproved new drugs. A prescription comes with a named prescriber, a licensed U.S. compounding pharmacy whose label says what's in the vial, and someone to call.
None of this adds up to a score. If the answer is no, the useful follow-up question is why.
A licensed provider reviews every request, and not everyone qualifies.
